Polish Pharmaceuticals & Biotech Potentially Undervalued Companies

Selvita

Market Cap: zł525.0m

Provides drug discovery, drug development, and contract testing services in Poland.

Bayer

Market Cap: zł48.4b

Operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.

Genomed Spólka Akcyjna

Market Cap: zł39.1m

Provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland.

Biogened

Market Cap: zł49.1m

Produces and sells cosmetics and toiletries in Poland.

Novo Nordisk

Market Cap: zł1.4t

Engages in the research and development, manufacture, and distribution of pharmaceutical products.

Tecnovatica

Market Cap: zł21.8m

Does not have significant operations.

Celon Pharma

Market Cap: zł1.2b

An integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products.

Krka d. d

Market Cap: zł7.9b

A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.

Eli Lilly

Market Cap: zł1.1t

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Ryvu Therapeutics

Market Cap: zł425.4m

A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.